- Research Letter
- Open Access
Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
Critical Care volume 25, Article number: 33 (2021)
Atrial fibrillation (AF) is frequent in shock patients admitted to the intensive care unit (ICU) [1, 2] and is associated with increased mortality . Several mechanisms are involved in the development of AF in the context of acute circulatory failure, including hypovolemia and β1-adrenergic stimulation in response to endogenous catecholamine production as well as norepinephrine infusion . Atrial fibrillation impairs left ventricular filling and consecutively stroke volume, and in fine potentially aggravates circulatory failure.
Pharmacological options to control AF-related tachycardia are limited. Calcium channel blockers are not frequently used because of long-term negative inotropic effects. Amiodarone is the most used drug but its optimal dosage to fine tune heart rate remains an issue, as well as its potential lung toxicity, especially in case of acute respiratory disease. Landiolol is a beta-blocker with highly β1 selective activity, used either in AF patients either to control heart rate or to prevent supraventricular arrhythmia occurrence in the context of cardiac surgery. Landiolol has an ultrashort half-life of 4 min and weaker negative inotropic effect compared with other intravenous β-blockers . A recent randomized controlled trial in patient with sepsis/septic shock developing tachyarrhythmia showed that Landiolol infusion efficiently reduced heart rate without any significant hemodynamic side effect .
Here, we described in critically ill patients admitted to the ICU for SARS-CoV-2 infections presenting with AF, our experience of Landiolol use in terms of efficacy and safety.
In our 18-bed intensive care unit, we prospectively collected data from adult patients admitted for SARS-CoV-2 infections with persistent AF. When heart rate was over 120 bpm, Landiolol was started at a minimum dose of 0.2 µg/kg/min and progressively increased by steps of 0.2–0.4 µg/kg/min every hour to achieve 20% reduction in heart rate, without bolus. Hemodynamic parameters were recorded every 2 h during the first 24 h of drug infusion.
Fifteen consecutive patients with SARS-CoV-2 infection were treated with Landiolol during a 6-month period. Median age was 70 [67–72] years old, 27% were female, and median SOFA score was 11 [7–12]. Six patients (6/15, 40%) had a history of chronic AF, and the other had recent AF resistant to electric cardioversion. Median left ventricular (LV) function was 55% [50–57] (Table 1) and no patient had LV ejection fraction < 40%. All included patients underwent invasive mechanical ventilation support and eleven (11/15, 73%) required norepinephrine. Median time between ICU admission and Landiolol initiation was 2 [0–5] days. Landiolol infusion was started at 0.2 µg/kg/min and dosage reached 3.9 [1.6–7.0] µg/kg/min at 24 h. Overall heart rate reduction was 23% (115 [108–117] vs 150 [138–160] bpm; p < 0.01, Wilcoxon signed-rank test), without any negative impact on global hemodynamic or tissue perfusion parameters (Table 1). Interestingly, during Landiolol infusion, norepinephrine need decreased in 9/11 patients (81%), and mean norepinephrine dose significantly decreased (0.7 [0.2–1] vs 1 [0.4–1.5] µg/kg/min; p = 0.04, Wilcoxon signed-rank test) (Fig. 1).
In this observational uncontrolled study, Landiolol was safely used to lower heart rate in critically ill patients with AF with normal or moderately altered cardiac function. Given that most patients under mechanical ventilation for SARS-CoV-2 infections received norepinephrine and that some of them had moderate left ventricular systolic function, Landiolol infusion was started at very low doses and maximal infusion rate at 24 h was lower than reported in studies on non-critically ill patients . Using this protocol, hemodynamic tolerance was excellent without any significant arterial hypotension or alteration in peripheral tissue perfusion. Moreover, we observed a decrease in norepinephrine need after Landiolol initiation. Additional studies are required to investigate the potential beneficial mechanisms of Landiolol on global hemodynamics.
Availability of data and materialS
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Steinberg I, Brogi E, Pratali L, Trunfio D, Giuliano G, Bignami E, Forfori F. Atrial fibrillation in patients with septic shock: a one-year observational pilot study. Turk J Anaesthesiol Reanim. 2019;47(3):213–9.
Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bogelein D, Gauss A, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care. 2010;14(3):R108.
Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–8.
Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985–9.
Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, et al. Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;9:863–72.
Matsuishi Y, Mathis BJ, Shimojo N, Kawano S, Inoue Y. Evaluating the therapeutic efficacy and safety of landiolol hydrochloride for management of arrhythmia in critical settings: review of the literature. Vasc Health Risk Manag. 2020;16:111–23.
Ethics approval and consent to participate
Not applicable for monocenter observational study.
Consent for publication
The authors declare that they have no competing interests. H.A.O. declares having received fees for medical trainings from the laboratories AMOMED.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hariri, G., Urbina, T., Mazerand, S. et al. Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients. Crit Care 25, 33 (2021). https://doi.org/10.1186/s13054-021-03470-3